P1.11-02. Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C
Back to course
Pdf Summary
Asset Subtitle
Baohui Han, China
Meta Tag
Speaker Baohui Han, China
Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
Shanghai Jiao Tong University
combination treatment strategy
non-small cell lung cancer
pan-KRAS mutation
KRASG12C mutation
MEK inhibitor
multi-targeted tyrosine kinase inhibitor
alternative treatment strategy
Powered By